Genetic testing for familial hypercholesterolaemia: Practical and ethical issues

QJM: An International Journal of Medicine

Volumn 90, Issue 3, 1997, Pages 169-181

  Humphries, S E ^a   Galton, D ^b   Nicholls, P ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIAGNOSIS; DIAGNOSTIC VALUE; DIET; DISEASE CARRIER; ENVIRONMENTAL FACTOR; ETIOLOGY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MEDICAL ETHICS; PRIORITY JOURNAL; REVIEW; RISK; SMOKING;

EID: 0030935105     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/90.3.169     Document Type: Review

References (76)

1. Nuffield Council on Bioethics Report on Genetic Screening - ethical issues (1993).
2. Bankowski Z, Capron AM. Genetics, ethics and human values. Proceedings of the XXIVth CIOMS Round Table Conference, 1991.
3. Qureshi N, Raeburn JA. Clinical Genetics meets primary care. Br Med J 1993; 307:816-17.
4. Post N. Ethical implications of screening asymptomatic individuals. FASEB J 1992; 6:2813-17.
5. Goldbourt U, Neufeld HN. Genetic aspects of Arteriosclerosis. Arteriosclerosis 1986; 6:357-77.
6. Goldstein JL, Brown MS. Familial hypercholesterolemia. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th edn. New York, McGraw-Hill, 1989:1215-50.
7. Tybjaerg-Hansen A, Gallagher J, Vincent J, Houlston R, Talmud P, Dunning AM, Seed M, Hamsten A, Humphries SE, Myant NB. Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases. Atherosclerosis 1990; 80:235-42.
8. Tybjaerg-Hansen A, Humphries S. Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolaemia and premature coronary artery disease. Atherosclerosis 1992; 96:91-107.
9. Heiberg A, Slack J. Familial similarities in the age at coronary death in Familial Hypercholesterolaemia. Br Med J 1977; 294:493-5.
10. Steering Committee of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br Med J 1992; 303:893-6.
11. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson G, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia. N Engl J Med 1990; 322:1494-9.
12. Streja D, Steiner G, Kwiterovich PO. Plasma high-density lipoproteins and ischaemic heart disease. Studies in a large kindred with familial hypercholesterolaemia. Ann Intern Med 1976; 89:871-80.
13. Kotze MJ, Davis HJ, Bisshort S, Langenhoven E, Brusnicky J, Oostlruizen CJJ. Intrafamilial variability in the clinical expression of familial hypercholesterolaemia: importance of risk factor determination for genetic counselling. Clin Genet 1993; 43:295-9.
14. Kwiterovich PO, Fredrickson DS, Levy RI. Familial hypercholesterolaemia (one form of familial type II hyperlipoproteinaemia)-A study of its biochemical, genetic and clinical presentation in childhood. JCI 1974; 53:1237-49.
15. Berenson GS, Srinivasan SR, Freedman DS, Radhakrishnamurthy B, Dalferes ER. Atherosclerosis and its evolution in childhood. Am J Med Sci 1987; 294:429-40.
16. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sulivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; (ii) 340:1111-15.
17. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546-50.
18. Nora JJ, Loitscher RM, Spangler RD, Bilheimer DW. Familial hypercholesterolaemics with 'normal' cholesterol in obligatory heterozygotes. Am J Med Genet 1985; 22:585-91.
19. Leonard JV, Whitelaw AGL, Wolff OH, Lloyd JK, Slack J. Diagnosing familial hypercholesterolaemia in children by measuring serum cholesterol. Br Med J 1977; 1:1566-8.
20. Koivisto PVI, Koivisto U-M, Miettinen TA, Kontula K. Diagnosis of heterozygous familial hypercholesterolaemia: DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb 1992; 12:584-92.
21. Ward AJ, O'Kane M, Nicholls DP, Young IS, Nevin NC, Graham CA. A novel single base deletion in the LDLR gene (211delG): Effect on serum lipid profiles and the influence of other genetic polymorphisms in the ACE, APOE and APOB genes. Atherosclerosis 1996; 120:83-91.
22. Kessling AM, Seed M, Taylor R, Wynn V, Humphries SE. Rising cholesterol levels in children with familial hypercholesterolaemia. Biomed Pharmacother 1990; 44:373-9.
23. Schmitz G, Bruning T, Kovacs E, Barlage S. Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in the differential diagnosis of hypercholesterolaemia. Arterioscler Thromb 1993; 13:1053-65.
24. Lestavel-Delattre S, Benhamamouch S, Agnani G, Luc G, Bard JM, Brousseau T, Billardon C, Kusnierz JP, De Gennes JL, Fruchart JC, Clavey V. Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolaemia profile. Metabolism 1994; 43:397-402.
25. Hobbs HH, Brown MS, Goldstein JL. Molecular Genetics of the LDL receptor gene in familial hypercholesterolaemia. Hum Mut 1992; 1:445-66.
26. Day INM, Whittall R, Haddad L, O'Dell S, Bolla M, Gudnason V, Humphries S. Spectrum of LDL receptor mutations in heterozygous familial hypercholesterolaemia: towards molecular diagnostics. Hum Mut 1997.
27. Sun X-M, Webb JC, Gudnason V, Humphries S, Seed M, Thompson GR, Knight BL, Soutar AK. Characterization of deletions in the LDL receptor gene in patients with familial hypercholesterolaemia in the United Kingdom. Arterioscler Thromb 1992; 12:762-70.
28. King-Underwood L, Gudnason V, Humphries S, Seed M, Patel D, Knight B, Soutar A. Identification of the 664 proline to leucine mutation in the low density lipoprotein receptor in four unrelated patients with familial hypercholesterolaemia in the UK. Clin Genet 1991; 40:17-28.
29. Webb JC, Sun XM, Patel DD, McCarthy SN, Knight BL, Soutar AK. Characterization of two point mutations in the low density lipoprotein receptor gene of an English patient with homozygous familial hypercholesterolaemia. J Lipid Res 1992; 33:689-98.
30. Gudnason V, King-Underwood L, Seed M, Sun X-M, Soutar AK, Humphries SE. Identification of recurrent and novel mutations in exon 4 of LDL receptor gene in patients with familial hypercholesterolaemia in the United Kingdom. Arterioscler Thromb 1993; 13:6-63.
31. Sun X-M, Patel DD, Bhatnagar D, Knight BL, Soutar AK. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb 1995; 15:219-227.
32. Graham CA, Ward AJ, Nevin NC, Trinick T, Young I, O'Kane M, Nicholls DP. Automated sequencing has identified 70% of mutations in 30 patients with familial hypercholesterolaemia in Northern Ireland. Atherosclerosis 1995; 112:261-267.
33. Ward AJ, O'Kane M, Young I, Nicholls DP, Nevin NC, Graham CA. Three novel mutations in the EGF precursor homology domain of the low density lipoprotein receptor gene in Northern Irish patients with familial hypercholesterolaemia. Hum Mut 1995; 6:254-6.
34. Gudnason V, Day I, Humphries SE. Effect on plasma lipid levels of mutations in exon 4 of the low-density lipoprotein receptor gene in patients with familial hypercholesterolaemia. Arterioscler Thromb 1994; 14:1717-21.
35. Whittall R, Gudnason V, Weavind G, Day LB, Humphries S, Day INM. Utilities for high throughput use of the single strand conformational polymorphism method: screening of 791 patients with familial hypercholesterolaemia patients for mutations in exon 3 of the low density lipoprotein receptor gene. J Med Genet 1995; 32:509-15.
36. Day INM, Haddad L, Day LB, O'Dell S, Whittall R, Humphries SE. Identification of a common low density lipoprotein receptor gene mutation (R329X) causing familial hypercholesterolaemia in the South of England. Complete linkage disequilibrium with an allele of hypervariable polymorphic marker D19S394. J Med Genet (in press).
37. Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993; 329:1308-13.
38. Cotton RGH. Current methods of mutation detection. Mutation Res 1993; 285:125-44.
39. Mashal RD, Koontz J, Sklar J. Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases. Nature Genetics 1995; 9:177-83.
40. Orita M, Sekiya T, Hayashi K. DNA sequence polymorphisms in Alu Repeats. Genomics 1990; 8:271-8.
41. Soutar AK. Familial Hypercholesterolaemia. In Humphries SE, Malcolm S, eds. From Genotype to Phenotype, Chapters, 1994:83-109.
42. Kotze MJ, De Villiers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven JS, Herbert JS, Graadt Van Roggen JF, Van der Westhuyzen DR, Coetzee GA. Phenotypic variation among familial hypercholesterolaemia heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993; 13:1460-8.
43. Jeenah M, September W, Graadt van Roggen F, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1993; 98:51-8.
44. Leitersdorf E, Eisenberg S, Eliav O, Freidlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, Bard J-M, Fruchart J-C, Stein Y. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolaemia. Circulation 1993; 87:35-44.
45. Tikannen MJ. Selection of appropriate type intensity of lipid-lowering therapy. Curr Opin Lipidol 1995; 6:360-4.
46. Kane JP, Malloy MJ, Ports TA, Philipps NR, Diehl JC, Havel J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolaemia with combined drug regimens. JAMA 1990; 264:3007-12.
47. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Scandinavian Simvastatin Survival Study Group. Lancet 1994; 344:1383-9.
48. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neiuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A. Familial hypercholesterolaemia regression study: a randomised trial of low density-lipoprotein apheresis. Lancet 1995; 345:811-16.
49. Smith GD, Song F and Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial levels of risk. Br Med J 1993; 306:367-71.
50. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH. Packark CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301-7.
51. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program. Pediatrics 1992; 89:525-84.
52. Wray R, Neil HAW, Rees JAE on behalf of the Committee of British Hyperlipidaemia Association. Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association, In press.
53. Keller C. LDL-apheresis: results of long term treatment and vascular outcome. Atherosclerosis 1991; 86:1-8.
54. Kwiterovich PO Jr. Pediatric implications of heterozygous familial hypercholesterolaemia. Screening and dietary treatment. Atherosclerosis 1989; 19:111-20.
55. West RJ, Lloyd JK. Long-term follow-up of children with FH treated with cholestyramine. Lancet 1980; ii:873-5.
56. Humphries S, King-Underwood L, Gudnason V, Seed M, Delattre S, Clavey V, Fruchart J-L. Six DNA polymorphisms in the low density lipoprotein-receptor gene: their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia. J Med Genet 1993; 30:273-9.
57. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva, WHO (Public Health Papers No 34), 1968.
58. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993; 16:325-32.
59. Bolla MK, Haddad L, Humphries SE, Winder AF, Day INM. A method for the rapid determination of hundreds of apoE genotypes, combining simplified, optimised protocols from sample acquisition to PCR and restriction digestion analysis by microplate array diagonal gel electrophoresis (MADGE). Clin Chem 1995; 41:1599-604.
60. Hayden MR, Josephson R. Development of a program for identification of patients with familial hypercholesterolaemia in British Columbia. A model for prevention of coronary disease. Am J Cardiol 1993; 72:25-9D.
61. Nuffield Council on Bioethics. Genetic Screening Ethical Issues. London, December 1993.
62. Harper PR. Research samples from families with genetic disease: a proposed code of conduct. Br Med J 1993; 306:1391-4.
63. Gudnason V, Patel D, Sun X-M, Humphries S, Soutar AK, Knight BL. (1995) Effect of the Stul polymorphism in the LDL-receptor gene (Ala 370 to Thr) on lipid levels in healthy individuals. Clin Genet 47:68-74.
64. Sun XM, Patel DD, Bhatnagar D, Knight BL, Soutar AK. Characterisation of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb Vasc Biol 1995; 15:219-27.
65. Flomen RH, Green PM, Bentley DR, Gianelli F, Green EP. Detection of point mutations and a gross deletion in six Hunter syndrome patients. Genomics 1992; 13:543-50.
66. Clarke A, Fielding D, Kerzin-Storrar, Middleton-Price H, Montgomery J, Payne H, Simonoff E, Tyle A. The genetic testing of children 1994.
67. Rosenthal SL, Knauer-Black S, Stahl MP, Catalanotto TJ, Sprecher DL. The psychological functioning of children with hypercholesterolemia and their families. Clin Pediatr 1993; 32:135-41.
68. Neil HAW, Mant D. Cholesterol screening and life assurance. BMA 1991; 302:891-3.
69. Harper PS. Insurance and Genetic Testing. Lancet 1993; 341:224-7.
70. The Ad Hoc Committee on Genetic Testing/Insurance Issues. Background Statement. Genetic testing and insurance. Am J Hum Genet 1995; 56:327-31.
71. Williams RR, Schumacher C, Barlow GK, Hunt SC, Ware JL, Pratt M, Latham BD. Documented need for more effective diagnosis and treatment of familial hypercholesterolaemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993; 72:18d-24d.
72. Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first degree relatives. Lancet 1972; i:1393-9.
73. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Van der Velden PA, Reitsma PJ. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-7.
74. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8:1-21.
75. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rosen R. A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10:111-13.
76. Cambien F, Poirier O, Lecerf L, Evans A, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641.